Avacta Initiates P-I Clinical Trial of AVA6000 in Soft Tissue Sarcoma at Two US Clinical Investigator Sites
Shots:
- The two US sites are added at the Memorial Sloan Kettering Cancer Center in New York and Fred Hutch Cancer Center in Seattle
- Patient enrolment at the US sites has been initiated for the P-I dose escalation study of AVA6000 (pre|CISION drug candidate) in soft tissue sarcoma and patients will receive the same doses at each stage of the trial as in the UK
- Followed by the favorable safety profile, the 5th cohort has received AVA6000 (250 mg/m2) in an ongoing P-Ia dose escalation study in the UK
Ref: Businesswire | Image: Avacta
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
